Related Experiment Video

Updated: Apr 14, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.2K

Histone deacetylase inhibitors: potent anti-leukemic agents

Jiang Bian, Lihui Zhang, Yantao Han

  • 1School of Pharmacy, Qingdao University, Qingdao, Shandong, 266071, China. cbwang666@126.com.

Current Medicinal Chemistry
|April 17, 2015
PubMed

Insights

Histone deacetylase inhibitors (HDACIs) show promise as targeted anti-leukemic agents. This review explores their potential to treat leukemia with improved safety and efficacy compared to traditional therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Leukemia is a prevalent and serious disease requiring novel therapeutic strategies.
  • Current anti-leukemic treatments face limitations in potency and side effect profiles.
  • Targeted therapies offer improved efficiency and safety in cancer treatment.

Purpose of the Study:

  • To review the anti-leukemic potential of histone deacetylase inhibitors (HDACIs).
  • To explore HDACIs as targeted agents for leukemia therapy.
  • To understand the preclinical efficacy of HDACIs against leukemia.

Main Methods:

  • Literature review of preclinical research on HDACIs and leukemia.
  • Analysis of studies investigating the selective inhibitory effects of HDACIs on leukemic cell lines.
  • Examination of approved HDACIs for cancer treatment.

Main Results:

  • HDACIs represent a class of targeted antitumor therapies.
  • Several HDACIs have demonstrated selective inhibitory effects on leukemic cell lines in preclinical studies.
  • Three HDACIs are currently FDA-approved for cancer treatment.

Conclusions:

  • HDACIs exhibit significant potential as anti-leukemic agents.
  • Targeted inhibition of histone deacetylases is a promising strategy for leukemia treatment.
  • Further investigation into HDACIs could lead to novel and safer leukemia therapies.

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

9.1K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.3K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.4K
Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
17.5K
Histone Modification02:32

Histone Modification

5.0K
Spreading of Chromatin Modifications02:25

Spreading of Chromatin Modifications

The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
10.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K